TOREMIFENE Drug Patent Profile
✉ Email this page to a colleague
When do Toremifene patents expire, and when can generic versions of Toremifene launch?
Toremifene is a drug marketed by MSN and Rising and is included in two NDAs.
The generic ingredient in TOREMIFENE is toremifene citrate. There are five drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the toremifene citrate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Toremifene
A generic version of TOREMIFENE was approved as toremifene citrate by RISING on December 4th, 2018.
AI Deep Research
Questions you can ask:
- What is the 5 year forecast for TOREMIFENE?
- What are the global sales for TOREMIFENE?
- What is Average Wholesale Price for TOREMIFENE?
Summary for TOREMIFENE
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 2 |
| DailyMed Link: | TOREMIFENE at DailyMed |
US Patents and Regulatory Information for TOREMIFENE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Msn | TOREMIFENE CITRATE | toremifene citrate | TABLET;ORAL | 212818-001 | Aug 18, 2020 | AB | RX | No | No | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| Rising | TOREMIFENE CITRATE | toremifene citrate | TABLET;ORAL | 208813-001 | Dec 4, 2018 | AB | RX | No | Yes | ⤷ Start Trial | ⤷ Start Trial | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |

